

Attorney Docket: 1830/50521  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MASAHIRO IMOTO ET AL.

Serial No.: TBA

Group Art Unit:

Filed: Herewith

Examiner:

Title: HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING  
NICOTINIC ACETYLCHOLINE ALFA4 BETA2 RECEPTOR

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §§ 1.97 and 1.98**

Commissioner for Patents  
Washington, D.C. 20231


Sir:

In accordance with the duty of disclosure under 37 CFR \$1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 C.F.R. \$1.97(e) or fee under 37 C.F.R. \$1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



Herbert I. Cantor  
Registration No. 24,392

CROWELL & MORING, LLP  
P.O. Box 14300  
Washington, DC 20044-4300  
Telephone No.: (202) 624-2500  
Facsimile No.: (202) 628-8844